Summary
Immunological disturbances with impairment of immune function and a higher incidence of lymphoproliferative disorders and other malignancies have been described in liver cirrhosis patients. To investigate the pathogenetic mechanism(s) involved in such associated we looked for a possible imbalance in peripheral blood T-lymphocyte subpopulations in patients with liver cirrhosis of differing severity. Immunophenotyping and counts of peripheral blood T-lymphocyte subpopulations were carried out using monoclonal antibodies conjugated with different fluorochromes in 31 consecutive cirrhotic patients and 23 matched healthy volunteers. Univariate and multivariate analyses of lymphocyte phenotype counts were performed and odds ratios were computed. Statistically significant associations, according to both univariate and multivariate analyses, were found between case/control status and mean CD3 and CD4 T-lymphocyte counts (P<0.0001). A strong correlation was found between the Pugh’s index and CD3 and CD4 lymphocyte counts, with a clear reduction of these phenotypes with increasing liver cirrhosis. Median CD3 and CD4 values were 2,283 and 1,329/μl respectively among controls and 896, 801, and 492/μl and 515, 514, and 307/μl, respectively in categories A, B, and C of Pugh’s classification. Very high odds ratios were found using the median values of CD3 and CD4 as a threshold. There was a statistically significant decrease for each of the T-cell phenotypes studied (CD2, CD3, CD4, CD8, CD16, CD19, CD20, CD56, CD57) between patients and controls (P<0.0001). The progressive and severity-related decrease in mean peripheral blood CD3 and CD4 counts in liver cirrhosis suggests a progressive impairment of protective immune function and may be a factor facilitating malignancy in cirrhotic patients.
Similar content being viewed by others
References
Zetterman RK, Sorell MF. Immunologic aspects of alcoholic liver disease. Gastroenterology 1981; 81:616.
MacSween RNM, Antony RS. Immunomechanisms in alcoholic liver disease. J Clin Lab Immuol 1982; 9:1.
Triger DR, Wright R. Hyperglobulinemia in liver disease. Lancet 1973; 1:1494.
Straus B, Berenyi MR, Huang JM. Delayed hypersensitivity in alcoholic cirrhosis. Am J Dig Dis 1971; 16:509.
Kawanishi H, Tavassolie H, MacDermott RP, Sheagren JN. Impaired concanavalin A-inducible suppressor T-cell activity in active alcoholic liver disease. Gastroenterology 1981: 80:510.
Charpentier B, Franco D, Paci L, Charra M, Martin B, Vuitton D, Fries D. Deficient natural killer cell activity in alcoholic cirrhosis. Clin Exp Immunol 1984; 58:107.
Hirifuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 1987; 68:348.
Nakamura T, Morizane T, Watanabe T, Tsuchimoto K, Inagaki Y, Kumagai N, Tsuchiya M. Decreased natural killer activity in patients with liver cirrhosis. Int J Cancer 1983; 32:573.
James SP, Jones EA. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells. Gastroenterology 1985; 89:165.
Son K, Kew M, Rabson AR. Depressed natural killer cell activity in patients with hepatocellular carcinoma. Cancer 1982; 50:2820.
Marx J. Natural killer cells help to defend the body. Science 1980; 7:624.
Hoffman T. Natural killer cell function in systemic lupus erythematosus. Arthritis Rheum 1980; 23:305.
Romagnani S. Type I I helper and type 2 helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991; 21:152.
Jovanovic R, Worner T, Lieber CS, Paronetto F. Lymphocyte subpopulations in patients with alcoholic liver disease. Dig Dis Sci 1985; 31:125.
Lombardo L, Rota Scalabrini D, Vineis P, De La Pierre M. Malignant lymphoproliferative disorders in liver cirrhosis. Ann Oncol 1993; 4:245.
Friedman SL, Millward-Sadler GH, Arthur MJP, Liver fibrosis and cirrhosis. In: Millward-Sadler, Wright R, Arthur MJP, eds. Liver and biliary disease, vol II. London: Saunders; 1992: 821–881.
Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973; 60:646.
Yamashita N, Maruyama M, Hamazaki K, Yano S. Effect of eicosapentaenoic and docosahexaenoic acid on natural killer cell activity in human peripheral blood lymphocytes. Clin Immunol Immunopathol 1991; 59:335.
Runyon BA, Carawati NH, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95:1351.
Jackson AL, Warner NL. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NL, Friedman H, Faley JL, eds. Manual of clinical laboratory immunology. 3rd edn. Washington, D.C.: American Society for Microbiology; 1986:226–235.
Muller C, Wolf H, Gottlicher J, Eibl MM. Phenotypic analysis of lymphocytes involved in major histocompatibility complex unrestricted cellular cytotoxicity in patients with alcoholic cirrhosis. Int Arch Allergy Appl Immunol 1990; 9:329.
Naor D. Short analytical review. A different outlook at the phenotype-function relationships of T cell subpopulations: fundamental and clinical implications. Clin Immunol Immunopathol 1992; 62:127.
De Horatius RJ, Strickland RG, Williams RC. T and B lymphocytes in acute and chronic hepatitis. Clin Immunol Immunopathol 1974; 2:253.
Thomas HC, Freni M, Sanchez Tapias J, et al. Peripheral blood lymphocyte populations in chronic liver disease. Clin Immunol 1976; 26:222.
Iwamoto H, Sakamoto S, Nawata H. Serum factor from patients with cirrhosis and hepatocellular carcinoma enhances production of prostaglandin E2 by U937 cells. Hepatology 1991; 14:1123.
Pritz H, Bjorneboe M, Christofersen P, et al. Correlation between hepatic morphology, immunoglobulins and antibodies toE. coli in cirrhosis. Gut 1977; 18:28.
Purtilo DT, Linder J. Oncological consequences of impaired immune surveillance against ubiquitous viruses. J Clin Immunol 1983; 3:197.
Heimann R, Ray MB, Desmet VJ. HBsAg, chronic lymphoproliferative disorders and cirrhosis of the liver. J Clin Pathol 1977; 30:817.
Naparstek J, Eliakim R. Malignant lymphoproliferative disorders in chronic liver diseases. Dig Dis 1978; 23:887.
Slavin S, Zlotnick A, Levij IC, Eliakim M. Clinical implication of monoclonal gammopathy in chronic liver disease. Am J Dig Dis 1974; 19:223.
Zawadzki ZA, Edwards GA. Dysimmunoglobulinemia associated with hepatobiliary disorders. Am J Med 1970; 48:196.
Sprent J, Webb SR. Function and specificity of T-cell subsets in the mouse. Adv Immunol 1987; 41:39.
Mason A, Yoffe B, Noonan C, Mearns M, Campbell C, Kelley A, Perrillo RP. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology 1992; 16:36.
Wright TL, Venook AP, Millward-Sadler GH. Hepatic tumours. In: Millward-Sadler, Wright R, Arthur MJP, eds. Wright’s liver and biliary disease. London: Saunders 1992:1079–1021.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lombardo, L., Capaldi, A., Poccardi, G. et al. Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. Int J Clin Lab Res 25, 153–156 (1995). https://doi.org/10.1007/BF02592558
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02592558